ModerateAlpha- and beta-blocker×Magnesium salt: intravenous solution and oral saline laxative
Updated · Methodology
Mechanism
The documents describe no pharmacokinetic interaction: labetalol is conjugated with glucuronic acid in the liver and its metabolites are excreted in urine and bile (labetalol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2), while magnesium is excreted by the kidneys (magnesium sulfate SmPC, AEMPS, section 5.2). Both drugs act on the heart and vessels. Labetalol slows the heart rate and atrioventricular conduction and lowers blood pressure (labetalol SmPC, AEMPS, sections 4.4 and 4.5). Magnesium sulfate requires caution in cardiac conduction disorders and is stopped if hypotension or bradycardia occurs (Sulmetin SmPC, AEMPS, section 4.4).
Symptoms
The documents describe no symptoms specific to the combination, but the warnings of both drugs include hypotension, bradycardia and cardiac conduction disorders (labetalol and magnesium sulfate SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). Magnesium can also impair neuromuscular transmission, and loss of the patellar reflex is a sign that the magnesium level is too high (Sulmetin SmPC, AEMPS, section 4.4).
Management
The combination can be used with caution, usually in hospital: intravenous magnesium sulfate is given only in hospital, blood pressure is monitored during injection and infusion, and serum magnesium is checked (Sulmetin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). Magnesium sulfate is stopped if hypotension or bradycardia occurs, serum magnesium exceeds 2.5 mmol/L or the patellar reflex disappears (Sulmetin SmPC, AEMPS, section 4.4). If symptomatic bradycardia develops on labetalol, its dose is reduced. Labetalol is given with caution in first-degree atrioventricular block (labetalol SmPC, AEMPS, section 4.4). In renal impairment the magnesium sulfate dose is reduced and renal function, blood pressure and magnesium are checked more often (Sulmetin SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Sulfato de magnesio, Sulmetin Simple 150 mg/ml solución inyectable y para perfusión (nº registro 23622), sección 4.3 (2025)– AEMPS, CIMA, nº registro 23622 (Sulmetin Simple 150 mg/ml solución inyectable y para perfusión, Desma Laboratorio Farmacéutico), revisión 02/2025, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Labetalol, Labetalol S.A.L.F. 5 mg/ml solución inyectable y para perfusión (nº registro 89082), sección 4.4 (2025)– AEMPS, CIMA, nº registro 89082 (Labetalol S.A.L.F. 5 mg/ml solución inyectable y para perfusión EFG), revisión 03/2025, secciones 4.1, 4.4, 4.5 y 5.2